MIM
VKTX icon

MetLife Investment Management’s Viking Therapeutics VKTX Stock Holding History

MetLife Investment Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83.7K Sell
2,146
-28
-1% -$904 ﹤0.01% 2803
2026
Q1 		$70.7K Sell
2,174
-23
-1% -$739 ﹤0.01% 2640
2025
Q4 		$77.3K Sell
2,197
-26
-1% -$921 ﹤0.01% 2672
2025
Q3 		$58.4K Buy
2,223
+18
+0.8% +$537 ﹤0.01% 2782
2025
Q2 		$58.4K Sell
2,205
-4,331
-66% -$114K ﹤0.01% 2675
2025
Q1 		$158K Sell
6,536
-14
-0.2% -$442 ﹤0.01% 2316
2024
Q4 		$264K Sell
6,550
-79
-1% -$4.5K ﹤0.01% 2158
2024
Q3 		$420K Sell
6,629
-130
-2% -$7.63K ﹤0.01% 1875
2024
Q2 		$358K Sell
6,759
-45,439
-87% -$2.98M ﹤0.01% 1912
2024
Q1 		$4.28M Buy
52,198
+1,501
+3% +$66.8K 0.03% 577
2023
Q4 		$943K Hold
50,697
– – 0.01% 1326
2023
Q3 		$561K Hold
50,697
– – ﹤0.01% 1556
2023
Q2 		$822K Buy
+50,697
New +$1.06M 0.01% 1377
2022
Q2 		– Sell
-7,040
Closed -$21.1K – 2908
2022
Q1 		$21.1K Sell
7,040
-19,437
-73% -$69.7K ﹤0.01% 2708
2021
Q4 		$122K Buy
26,477
+11,454
+76% +$64.2K ﹤0.01% 2332
2021
Q3 		$94.3K Sell
15,023
-12,499
-45% -$77.2K ﹤0.01% 2464
2021
Q2 		$165K Buy
27,522
+18,376
+201% +$109K ﹤0.01% 2270
2021
Q1 		$57.8K Sell
9,146
-20,668
-69% -$145K ﹤0.01% 2279
2020
Q4 		$168K Buy
29,814
+1,212
+4% +$7.34K ﹤0.01% 2074
2020
Q3 		$166K Hold
28,602
– – ﹤0.01% 1970
2020
Q2 		$206K Hold
28,602
– – ﹤0.01% 1887
2020
Q1 		$134K Hold
28,602
– – ﹤0.01% 1920
2019
Q4 		$229K Hold
28,602
– – ﹤0.01% 1906
2019
Q3 		$197K Hold
28,602
– – ﹤0.01% 1958
2019
Q2 		$237K Hold
28,602
– – ﹤0.01% 1927
2019
Q1 		$284K Hold
28,602
– – ﹤0.01% 1779
2018
Q4 		$219K Buy
28,602
+6,905
+32% +$82.6K ﹤0.01% 1858
2018
Q3 		$378K Hold
21,697
– – ﹤0.01% 1713
2018
Q2 		$206K Buy
+21,697
New +$144K ﹤0.01% 1908

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

MetLife Investment Management's VKTX Position: Q2 2026 in Review

MetLife Investment Management reduced its Viking Therapeutics (VKTX) stake by 1.3% in Q2 2026, selling an estimated $904 and leaving 2,146 shares worth $83.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2803.

MetLife Investment Management first reported a position in VKTX in Q2 2018 and has held it in 29 quarters since. The position peaked at $4.28M in Q1 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • MetLife Investment Management held 2,146 shares of Viking Therapeutics worth $83.7K as of Q2 2026.
  • MetLife Investment Management sold 28 Viking Therapeutics shares in Q2 2026, an estimated $904.
  • Viking Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2803 holding.
  • MetLife Investment Management first reported a position in Viking Therapeutics in Q2 2018 and has held it in 29 quarters since.
  • MetLife Investment Management's Viking Therapeutics position peaked at $4.28M in Q1 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.